FDA Approves Lilly/BI Diabetes Drug Synjardy
This article was originally published in Scrip
Executive Summary
The FDA on Aug. 27 cleared Lilly's and Boehringer Ingelheim's type 2 diabetes medicine Synjardy – the third empagliflozin-containing drug approved for the US market.